Asia’s strong equity deals pipeline to be tested by AI bubble concerns in 2026

Asian equity capital markets have strengthened this year with ECM issuance at $267 billion YTD, up 15% from 2024, led by Hong Kong with $75 billion (the highest since 2021) and India raising $19.3 billion in IPOs (down 6% from last year; Meesho’s $604m IPO not yet included). Large second listings and landmark offerings (CATL $5.3bn, Zijin Gold International $3.5bn, prospective Reliance Jio and Zhongji Innolight deals) and over 300 Hong Kong filings point to a strong 2026 pipeline, but potential AI valuation risks and a rotation away from U.S. assets amid political uncertainty could pressure deal pricing and valuations.

Analysis

Market structure: Heavy IPO pipeline in Hong Kong and India (300+ Hong Kong filings; India ~$20bn IPO potential in 2026) shifts primary issuance and fee pools to Asia—winners are HKEX, lead banks (Goldman Sachs, ticker GS), and large issuers (CATL, Zijin), losers are U.S. growth/momentum names if capital rotates. Increased supply of primary equity will flatten short-term secondary aftermarket pricing (deal discounts likely 5–15% vs last private rounds) but strong cross-border demand can absorb supply if risk appetite holds.

Risk assessment: Tail risks include a China regulatory shock (AI/data security clampdown) or a contagious AI de-rating in US that triggers 20–30% markdowns in high-multiple AI names and squeezes IPO pricing; geopolitical/trade escalation under U.S. policy could reverse flows within 30–90 days. Near-term (days-weeks) volatility will cluster around major IPO windows and US macro prints; medium-term (3–12 months) depends on Fed path and earnings revision; long-term (12–36 months) favors structural Asia growth if economic momentum continues.

Trade implications: Tactical edge is to capture fee/flow shift and valuation dispersion: buy Asia-ex-Japan equity exposure (AAXJ) and India (INDA) into expected 2026 deal flow, paired with selective hedges on U.S. AI beta (QQQ). Use options around known IPO dates—buy 2–3 month call spreads on INDA/AAXJ and 1–2 month put spreads on QQQ to limit cost. Rotate from highest-multiple US AI names toward cyclical EM tech, battery/materials (LIT) where revenue visibility is clearer.

Contrarian angles: Consensus assumes Asia IPOs equal easy gains—misses execution risk: secondary lockups, weak retail demand, and valuation resets post-IPO. If AI selloff continues, India (AI-underweight) could outperform more than priced; conversely, a China policy easing would disproportionately re-rate HK large caps. Historical parallel: 2014–15 China IPO waves delivered short-term dispersion and long-term concentration in winners; position sizing and event-specific hedges matter.

Key Decisions for Investors

• Establish a 2–3% long position in GS (Goldman Sachs) within 2–6 weeks to capture higher ECM fee pools from HK/India listings; trim if GS trades >15% above entry or if announced deal pipeline falls below 70% of current filings.
• Allocate 3–5% long to AAXJ and 2–3% long to INDA (stagger entries over 4 weeks); hedge with a 1% notional short in QQQ (or buy 1% notional 1–2 month put spread on QQQ) to protect against a clustered AI de-rating.
• Buy 3–6 month call spreads on INDA (buy 1.5 month ATM, sell 3 month +6% strike) sized at 0.5–1% of portfolio to leverage expected 2026 India IPO momentum while capping premium paid.
• Reduce exposure to top-tier US AI high-multiple names by 25–40% if portfolio weight to NVDA/other mega-caps exceeds 6% total; redeploy proceeds into LIT (1–2% position) and selected HK large-cap cyclicals (EWH, 2% exposure) to capture rotation into Asia.
• Monitor China regulatory signals closely—if MIIT/PBOC or State Council issues restrictive AI/data-security guidance within the next 60 days, immediately cut China/HK IPO exposure by 50% and move hedges to 2–3% put notional on AAXJ/EWH.